SCHEMBL5357007

SCHEMBL5357007

Oc1cc2c(c3ccccc13)CCN2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.41
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 2/20 0.41
HPGD P15428 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
TRPM4 Q8TD43 1/20 0.39
PNMT P11086 1/20 0.39
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
NOTUM Q6P988 1/20 0.39
PARP1 P09874 2/20 0.39
IDO1 P14902 1/20 0.38
LMNA P02545 2/20 0.37
ACHE P22303 2/20 0.37
BCHE P06276 1/20 0.37
ALDH1A1 P00352 2/20 0.35
HTR5A P47898 1/20 0.35
NISCH Q9Y2I1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5369195 0.89 PRKD1 (0.42) HTTKDM4EMEN1KMT2ATRPM4
SCHEMBL18403202 0.80 PNMT (0.53) HTTKDM4EMEN1HPGDKMT2A
SCHEMBL5865674 0.78 KDM4E (0.42) HTTKDM4EMEN1HPGDKMT2A
SCHEMBL5649180 0.78 BCHE (0.43) HTTKDM4EMEN1HPGDKMT2A
SCHEMBL13349977 0.77 PARP1 (0.40) HTTDRD2DRD4NOTUMPARP1
SCHEMBL25786097 0.76 MAPT (0.49) KDM4EMEN1HPGDKMT2ACYP1A2
SCHEMBL5365445 0.75 DRD2 (0.37) DRD2DRD4NOTUMPARP1ACHE
SCHEMBL28626057 0.75 BCHE (0.38) HTTKDM4EMEN1HPGDKMT2A
SCHEMBL16847839 0.72 BCHE (0.34) HTTKDM4EMEN1HPGDKMT2A
SCHEMBL20801835 0.72 HTT (0.49) HTTKDM4EMEN1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7214685-B2 Prodrugs for a selective cancer therapy Tietze, Lutz F. (DE) 2007-05-08 US claimed
EP-1280771-B1 NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO 3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY TIETZE LUTZ F PROF DR (DE) 2004-10-13 EP claimed
US-20040033962-A1 Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo[3,2-e]indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo[f]quinoline derivatives for use in selective cancer therapy TIETZE, LUTZ F. (DE) 2004-02-19 US claimed
EP-1280771-A2 NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO 3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY Tietze, Lutz F., Prof. Dr. (DE) 2003-02-05 EP claimed
WO-2001083448-A2 NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO[3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO[F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY TIETZE LUTZ F (DE) 2001-11-08 WO claimed
EP-3082875-B1 PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF GENENTECH INC (US) 2020-11-25 EP disclosed
EP-3191135-B1 ANTI-HER2 ANTIBODIES AND IMMUNOCONJUGATES GENENTECH INC (US) 2020-08-19 EP disclosed
EP-2097097-B1 ANTIBODIES, IN PARTICULAR HUMAN ANTIBODIES, THAT BIND CD22 AND USES THEREOF SQUIBB & SONS LLC (US) 2018-05-30 EP disclosed
EP-2173739-B1 SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES SYNTARGA BV (NL) 2013-07-31 EP disclosed
WO-2008103693-A2 CHEMICAL LINKERS WITH SINGLE AMINO ACIDS AND CONJUGATES THEREOF MEDAREX, INC. (US) 2008-08-28 WO disclosed
WO-2008083312-A2 CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF MEDAREX, INC. (US) 2008-07-10 WO disclosed
WO-2008070569-A2 HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF MEDAREX, INC. (US) 2008-06-12 WO disclosed
EP-1280771-B1 NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO 3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY TIETZE LUTZ F PROF DR (DE) 2004-10-13 EP disclosed
US-20040033962-A1 Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo[3,2-e]indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo[f]quinoline derivatives for use in selective cancer therapy TIETZE, LUTZ F. (DE) 2004-02-19 US disclosed
US-20040033962-A1 Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo[3,2-e]indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo[f]quinoline derivatives for use in selective cancer therapy TIETZE, LUTZ F. (DE) 2004-02-19 US disclosed
EP-1280771-A2 NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO 3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY Tietze, Lutz F., Prof. Dr. (DE) 2003-02-05 EP disclosed
EP-1280771-A2 NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO 3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY Tietze, Lutz F., Prof. Dr. (DE) 2003-02-05 EP disclosed
WO-2001083448-A3 NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO[3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO[F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY TIETZE LUTZ F (DE) 2002-06-20 WO disclosed
WO-2001083448-A2 NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO[3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO[F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY TIETZE LUTZ F (DE) 2001-11-08 WO disclosed
WO-2001083448-A2 NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO[3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO[F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY TIETZE LUTZ F (DE) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040033962-A1 Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo[3,2-e]indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo[f]quinoline derivatives for use in selective cancer therapy DHPS, DERA, DUT HTT 1471/4885KDM4E 321/4885MEN1 3138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.